Answers are grounded in this paper and cite their sources.
BACKGROUND: In the past years the bone seeking radiopharmaceutical samarium lexidronam ((153)Sm-EDTMP) has been increasingly used alone or in conjunction with chemotherapy and/or bisphosphonates for the treatment of painful bone metastasis. OBJECTIVE: Its use has been explored in different solid tumours. In this report we explore its interesting characteristics and describe our experience in multiple myeloma (MM). METHODS: (153)Sm-EDTMP has an affinity for bone and concentrates in areas of bone turnover. It decays as a therapeutic beta-emission and at the same time as gamma-photon that can be used for tracking its concentration with bone scan imaging. Ten patients with symptomatic MM were treated to achieve pain control. RESULTS: Encouraging results were obtained in MM patients. The use of this radioisotope could be largely improved.
No takes yet. Share an insight, caveat, or question.
Abruzzese et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: